Metabolic characteristics of patients with type 2 diabetes mellitus who experienced post-COVID syndrome

October 11, 2024
368
УДК:  616.379-008.64+578.834.1+577.121
Resume

Purpose: to evaluate changes in metabolic parameters of patients with type 2 diabetes mellitus (T2DM) who had/did not have post-COVID syndrome to predict the further course of T2DM.

Object and research methods. 121 patients with T2DM were included in the prospective study: 60 patients with post-COVID syndrome and 61 who did not experience post-COVID syndrome. The assessment of vitamin D availability was carried out using the «25-hydroxycalciferol» test, which was performed by the CLIA method, a chemiluminescent immunoassay. Determination of liver enzymes, magnesium, uric acid were condacted by colorimetric method. Glycated hemoglobin was determined using the method of high-performance liquid chromatography. The HOMA insulin resistance index was calculated using the formula: HOMA index = glucose (in venous blood) x insulin/22.5.

Results. During the analysis, a higher level of body mass index, waist circumference, aspartate aminotransferase, glycated hemoglobin, HOMA index and a lower level of 25-hydroxyvitamin D (25-OH D) (p<0.05) were obtained in comparison with patients without post-COVID syndrome. No significant difference was found between the groups of patients who experienced post-COVID syndrome and those who did not have post-COVID syndrome, according to the following indicators: age, history of T2DM, alanine aminotransferase, uric acid, magnesium.

Conclusion. The obtained data indicate the possibility of predicting a more severe course of T2DM in patients with post-COVID syndrome, which requires careful monitoring and compensation of carbohydrate metabolism due to the correction of the scheme of antidiabetic therapy and vitamin D deficiency.

References

  • 1. Fernandez-de-las-Peñas C., Notarte K.I., Macasaet R. et al. (2024) Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis. J. Infecti., 88(2): 77–88.
  • 2. IDF atlas, 21th edition. diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf.
  • 3. Kohut A.O., Chaban O.S., Burdeinyi A.O. et al. (2022) Post-COVID cognitive impairment in patients with type 2 diabetes mellitus. Wiad. Lek., 75(8 pt 1): 1895–1899.
  • 4. Kohut M., Bobryk M., Komisarenko J. et al. (2021) The features of cognitive impairments in patients with type 2 diabetes mellitus and comorbid post covid disorders. Psychosomatic Medicine and General Practice, 6(1). doi: 10.26766/pmgp.v6i1.334.
  • 5. Бобрик М., Комісаренко Ю. (2024) Оцінка важкості стресу у пацієнтів з цукровим діабетом 2 типу в залежності від рівня забезпеченості вітаміном Д. PMGP, 9(3): e0903538.
  • 6. Pashkovska N. (2023) Cognitive impairment in type 2 diabetes mellitus: prospects for the use of metformin. Int. J. Endocrinol. (Ukraine), 19(3): 215–224.
  • 7. Kincaid K.J., Kung J.C., Senetar A.J. et al. (2021) Postcovid seizure: A new feature of «long-COVID». Eneurological. Sci., 23: 100340. doi: 10.1016/j. ensci.2021.100340.
  • 8. Silva N.M.L.E., Barros-Aragão F.G.Q., De Felice F.G. et al. (2022) Inflammation at the crossroads of COVID-19, cognitive deficits and depression. Neuropharmacology, 209: 109023. doi: 10.1016/j. neuropharm.2022.109023.
  • 9. Bandeira I.P., Schlindwein M.A.M., Breis L.C. et al. (2021) Neurological Complications of the COVID-19 Pandemic: What Have We Got So Far? Adv. Exp. Med. Biol., 1321: 21–31. doi: 10.1007/978-3-030- 59261-5_2.